Investor alert: law offices of howard g. smith commences investigation on behalf of novo nordisk a/s investors

Bensalem, pa.--(business wire)--law offices of howard g. smith announces an investigation on behalf of novo nordisk a/s (“novo nordisk” or the “company”) (nyse: nvo) investors concerning the company and its officers’ possible violations of federal securities laws. novo nordisk is a healthcare company that engages in the discovery, development, manufacture and marketing of pharmaceutical products worldwide. the company has allegedly colluded with other insulin producers to fix prices. on august 5, 2016, novo nordisk disclosed disappointing earnings for the second quarter of 2016, shrinking its predictions for sales growth and reporting the loss of a contract with a large u.s. pharmacy benefit manager (“pbm”). on this news, novo nordisk’s american depositary receipt (“adr”) price fell over 9% on august 5, 2016. then, on october 28, 2016, novo nordisk announced its second consecutive quarter of disappointing earnings and cut its long-term profit-growth forecasts by 50%. additionally, the company also acknowledged receipt of a civil investigative demand from the u.s. attorney’s office for the southern district of new york for information concerning novo nordisk’s contracts and business relationships with pbms related to certain of the company’s insulin products. on this news, novo nordisk’s adr price fell over 12% on october 28, 2016. if you purchased novo nordisk adrs, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact howard g. smith, esquire, of law offices of howard g. smith, 3070 bristol pike, suite 112, bensalem, pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
NVO Ratings Summary
NVO Quant Ranking